I 
118TH CONGRESS 
1ST SESSION H. R. 3684 
To direct the Secretary of Defense to establish a grant program for using 
psychedelic substances to treat certain conditions, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 25, 2023 
Mr. CRENSHAW (for himself, Mr. LUTTRELL, Mr. BERGMAN, Ms. MACE, Mr. 
GAETZ, Ms. OCASIO-CORTEZ, Mr. MOSKOWITZ, Mr. ZINKE, Ms. LEE of 
Florida, Mr. CORREA, and Mr. VAN ORDEN) introduced the following bill; 
which was referred to the Committee on Armed Services 
A BILL 
To direct the Secretary of Defense to establish a grant 
program for using psychedelic substances to treat certain 
conditions, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Douglas ‘Mike’ Day 
Psychedelic Therapy to Save Lives Act of 2023’’. 
VerDate Sep 11 2014 
00:18 Jun 20, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3684.IH
H3684
pbinns on DSKJLVW7X2PROD with $$_JOB
SEC. 2. GRANT PROGRAM OF THE DEPARTMENT OF DE-
FENSE TO STUDY TREATMENT OF CERTAIN 
CONDITIONS USING CERTAIN PSYCHEDELIC 
SUBSTANCES. 
(a) ESTABLISHMENT.—Not later than 90 days after 
the date of enactment of this Act, the Secretary of Defense 
shall award grants to eligible entities to conduct research 
on the treatment of members of the Armed Forces serving 
on active duty with a covered condition using covered psy-
chedelic substances. Not later than 60 days after the date 
of the enactment of this Act, the Secretary shall designate 
a lead administrator to carry out the grant program under 
this section. 
(b) ELIGIBLE ENTITIES.—The Secretary may award 
a grant under this section to any of the following: 
(1) A department or agency of the Federal Gov-
ernment or a State government. 
(2) An academic institution. 
(3) A nonprofit entity. 
(c) USE OF GRANT FUNDS.—A recipient of a grant 
awarded under this section may use the grant to— 
(1) conduct one or more phase two clinical 
trials for the treatment of covered conditions that— 
(A) include members of the Armed Forces 
serving on active duty as participants in the 
clinical trial; and 
VerDate Sep 11 2014 
00:18 Jun 20, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3684.IH
H3684
pbinns on DSKJLVW7X2PROD with $$_JOB
(B) use individual or group therapy as-
sisted by covered psychedelic substances; or 
(2) train practitioners to provide treatment to 
members of the Armed Forces serving on active duty 
for covered conditions using covered psychedelic sub-
stances. 
(d) PARTICIPATION IN CLINICAL TRIALS.—The Sec-
retary shall authorize any member of the Armed Forces 
diagnosed with a covered condition to participate in a clin-
ical trial that is conducted using a grant awarded under 
this section or funds provided under subsection (e) and 
is authorized pursuant to section 505 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355), without regard 
to— 
(1) whether the clinical trial involves a sub-
stance included in the schedule under section 202 of 
the Controlled Substances Act (21 U.S.C. 812); or 
(2) section 912a of title 10, United States Code 
(article 112a of the Uniform Code of Military Jus-
tice). 
(e) ADDITIONAL AUTHORITY.—In addition to award-
ing grants under this section, the Secretary shall provide 
funds for a clinical research trial using covered psychedelic 
substances that is authorized pursuant to section 505 of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
VerDate Sep 11 2014 
00:18 Jun 20, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3684.IH
H3684
pbinns on DSKJLVW7X2PROD with $$_JOB
355) and includes members of the Armed Forces as par-
ticipants in the trial. 
(f) REPORT REQUIRED.—Not later than 180 days 
after the date of the enactment of this Act, and every 180 
days thereafter, the Secretary shall submit to the Commit-
tees on Armed Services of the House of Representatives 
and the Senate a report on grants awarded under this sec-
tion, including the following: 
(1) Identification of clinics designated to host 
activities under such a grant. 
(2) A description of entities to whom the Sec-
retary has awarded such a grant. 
(3) The number of members of the Armed 
Forces who participated in a clinical trial described 
in subsection (d). 
(4) Information on the findings of such clinical 
trials. 
(g) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Secretary to carry 
out this section $15,000,000 for each of fiscal years 2024 
through 2028. 
(h) DEFINITIONS.—In this section: 
(1) The term ‘‘covered condition’’ means any of 
the following: 
(A) Post-traumatic stress. 
VerDate Sep 11 2014 
00:18 Jun 20, 2023
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3684.IH
H3684
pbinns on DSKJLVW7X2PROD with $$_JOB
(B) Traumatic brain injury. 
(C) Chronic traumatic encephalopathy 
(2) The term ‘‘covered psychedelic substances’’ 
means any of the following: 
(A) 3,4-Methylenedioxy-methamphetamine 
(commonly known as ‘‘MDMA’’). 
(B) Psilocybin. 
(C) Ibogaine. 
(D) 
5-Methoxy-N,N-dimethyltryptamine 
(commonly known as ‘‘5-MeO-DMT’’). 
(3) The term ‘‘State’’ has the meaning given 
such term in section 901 of title 32, United States 
Code. 
Æ 
VerDate Sep 11 2014 
00:18 Jun 20, 2023
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H3684.IH
H3684
pbinns on DSKJLVW7X2PROD with $$_JOB